fda compounding semaglutide news november 2025 The FDA's Decision to Ban Compounds: What You Need to Know The Risks of Compounded Semaglutide
Description
PlexusDx has successfully treated patients across all adult age groups with appropriate medical oversight
The FDA states that exenatide, the first GLP-1 receptor agonist, is being phased out as of January 2025 due to a GLP-1 scarcity
Mechanism of action comparison: amylin vs triple agonism Understanding the mechanistic differences between cagrilintide and retatrutide is not just academic
Grace period for missed doses because Retatrutide remains active for several days beyond the 7-day window, patients who miss an injection may still maintain partial therapeutic coverage
Less common but more serious: pancreatitis, gastroparesis, bowel obstruction, blockages, or gallstones
